U.S. panel split on Pfizer rare disease drug Fri May 25, 2012 12:37am EDT (Reuters) - A U.S. health advisory panel on Thursday issued a split vote on data for Pfizer Inc's drug to treat a rare neurodegenerative disease. The U.S. Food and Drug Administration panel voted 13 to 4 that the drug did not show that it met the main goal in a study in treating the fatal condition. However, the panel also voted 13 to 4 that the drug treated a surrogate endpoint, which may correlate with treating the underlying disease. The headline and story has been corrected to show FDA panel voted against one aspect of the drug's efficacy, but approved another.